Clinical Trial Update: Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD

View source ↗

Summary

Novartis is conducting a clinical trial evaluating LDL-C changes and adherence to inclisiran in a population including primary hypercholesterolemia and mixed dy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Hypercholesterolemia
• Mixed Dyslipidemia

Drugs mentioned

• Inclisiran (inclisiran)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Primary Hypercholesterolemia, Mixed Dyslipidemia | Status: ACTIVE_NOT_RECRUITING